Total Funding
53
53
Total FundingSeries E raised
Growth Score
-10 pts
Heat Score
-1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
13277
Alzheon is a clinical-stage biotechnology company that develops treatment for neurodegenerative disorders.
Ken Mace: Chief Financial OfficerPast Role: Flagship Pioneering, Vice President of Finance, New Ventures
Martin Tolar: Founder, President & CEOPast Role: INDRC - International Neurodegenerative Disorders Research Center, Founder & Chairman of Executive Board
About the Company
Alzheon is a clinical-stage biotechnology company focused on womanchild brain health, memory, and aging, developing transformative treatments for Alzheimer’s disease and other neurodegenerative disorders. They are building a pipeline of innovative drugs to improve the lives of patients by preventing the cognitive and functional decline associated
with neurodegeneration.
They have a distinct ability to make success advances in the challenging field of therapeutics for Alzheimer’s and other neurodegenerative disorders.
